株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

代謝医薬品市場 - 市場規模、シェア、動向、予測 ~2026年

Metabolism Drugs Market - Size, Share, Trends, and Forecast till 2026

発行 Coherent Market Insights 商品コード 785767
出版日 ページ情報 英文 167 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.95円で換算しております。
代謝医薬品市場 - 市場規模、シェア、動向、予測 ~2026年 Metabolism Drugs Market - Size, Share, Trends, and Forecast till 2026
出版日: 2018年07月16日 ページ情報: 英文 167 Pages
概要

United Pompe Foundation(UPF)は、2017年のオランダにおけるポンペ病罹患数は4万人に1人、中国南部および台湾においては5万人に1人、アフリカ系アメリカ人では1万4000人に1人、コーカソイドでは10万人に1人と推計しています。ポンペ病の罹患率の上昇や、医薬品の研究開発に対する政府イニシアチブなどが代謝医薬品市場の成長を支えています。

当レポートでは、世界の代謝医薬品市場を調査し、市場の概要、治療タイプ・用途・流通チャネル・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場の視野

  • レポート概要
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 市場スニペット:治療タイプ別
    • 市場スニペット:用途別
    • 市場スニペット:流通チャネル別
    • 市場スニペット:地域別
  • コヒーレント商談マップ(COM)

第3章 市場力学、規制、市場動向の分析

  • 市場力学
    • 成長要因
    • 阻害要因
    • 市場機会
  • 影響分析
  • PEST分析
  • ファイブフォース分析
  • 規制シナリオ

第4章 世界の代謝医薬品市場:治療タイプ別

  • イントロダクション
  • 酵素補充療法(ERT)
  • 基質合成抑制療法(SRT)
  • 低分子治療薬
  • その他

第5章 世界の代謝医薬品市場:用途別

  • イントロダクション
  • 糖原病
  • 脂質代謝異常症
  • アミノ酸代謝異常症
  • その他

第6章 世界の代謝医薬品市場:流通経路別

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 世界の代謝医薬品市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • 中南米
  • アフリカ
  • 中東

第8章 競争環境

  • 企業プロファイル
    • Merck & Co., Inc.
    • Novartis AG
    • Amicus Therapeutics
    • AstraZeneca Plc
    • Boehringer Ingelheim
    • Shire Plc
    • Sanofi Genzyme
    • BioMarin Pharmaceutical, Inc.
    • Horizon Pharma Plc
    • GlaxoSmithKline Plc

第9章 セクション

  • 参考文献
  • 調査方法
  • Coherent Market Insightsについて
目次

Increasing prevalence of pompe disease is expected to create lucrative opportunities for pharmaceutical manufacturers to develop and commercialize novel treatments for the disease. For instance, according to United Pompe Foundation (UPF), 2017, the estimated incidence of Pompe disease in Holland is 1 in 40,000, in Southern China and Taiwan: 1 in 50,000 births, African-Americans: 1 in 14,000 births and in Caucasian is 1 in 100,000 population. Initiatives from government organizations for drug research and development is supporting growth of the metabolism drugs market.

For instance, in 2016, the scientist from National Institutes of Health researchers collaborated with National Institute of Neurological Disorders and Stroke (NINDS) and the National Center for Advancing Translational Sciences (NCATS) and researchers identified a new molecule that shows promising approach for treatment of the rare gaucher disease. Moreover, in 2014, European Gaucher Alliance launched Gaucher Awareness Day to spread awareness about this rare disease among the population in Europe.

Market Dynamics

Robust pipeline with various therapies such as enzyme replacement therapy, gene therapy, and small molecule drugs is expected to boost the metabolism drugs market over the forecast period. Increased understanding of diseases and rising number of diagnosed patients are expected to increase the number of patients undergoing treatment.

High prevalence of metabolic diseases is expected to support the growth of the metabolism drugs market. For instance, according to the National Institute of Health (NIH) 2018 report, frequency of hunter syndrome is 1 in 100,000 to 1 in 160,000 in males. Enzyme replacement therapy is expected to show significant growth in the metabolism drugs market over the forecast period.

Key features of the study:

This report provides in-depth analysis of metabolism drugs market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new application launches or approval, regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global metabolism drugs market based on the following parameters – company overview, financial performance, application portfolio, geographical presence, distribution strategies, key developments, and strategies

Key companies covered as a part of this study include Merck & Co., Inc., Novartis AG, Amicus Therapeutics, AstraZeneca Plc, Boehringer Ingelheim, Shire Plc, Sanofi Genzyme, BioMarin Pharmaceutical, Inc., Horizon Pharma Plc, and GlaxoSmithKline Plc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future application launches, technology up-gradation, market expansion, and marketing tactics

The global metabolism drugs market report caters to various stakeholders in this industry including investors, suppliers, application manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the metabolism drugs market

Detailed Segmentation:

  • Global Metabolism Drugs Market, By Therapy Type:
  • Enzyme Replacement Therapy
  • Substrate Reduction Therapy
  • Small Molecule Drugs
  • Others
  • Global Metabolism Drugs Market, By Application:
  • Glycogen Metabolism Disease
  • Lipid Metabolism Disease
  • Amino Acid Metabolism Disease
  • Others
  • Global Metabolism Drugs Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Metabolism Drugs Market, By Geography:
  • North America
  • By Therapy Type:
  • Enzyme Replacement Therapy
  • Substrate Reduction Therapy
  • Small Molecule Drugs
  • Others
  • By Application:
  • Glycogen Metabolism Disease
  • Lipid Metabolism Disease
  • Amino Acid Metabolism Disease
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • U.S.
  • Canada
  • Europe
  • By Therapy Type:
  • Enzyme Replacement Therapy
  • Substrate Reduction Therapy
  • Small Molecule Drugs
  • Others
  • By Application:
  • Glycogen Metabolism Disease
  • Lipid Metabolism Disease
  • Amino Acid Metabolism Disease
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Therapy Type:
  • Enzyme Replacement Therapy
  • Substrate Reduction Therapy
  • Small Molecule Drugs
  • Others
  • By Application:
  • Glycogen Metabolism Disease
  • Lipid Metabolism Disease
  • Amino Acid Metabolism Disease
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • By Therapy Type:
  • Enzyme Replacement Therapy
  • Substrate Reduction Therapy
  • Small Molecule Drugs
  • Others
  • By Application:
  • Glycogen Metabolism Disease
  • Lipid Metabolism Disease
  • Amino Acid Metabolism Disease
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East
  • By Therapy Type:
  • Enzyme Replacement Therapy
  • Substrate Reduction Therapy
  • Small Molecule Drugs
  • Others
  • By Application:
  • Glycogen Metabolism Disease
  • Lipid Metabolism Disease
  • Amino Acid Metabolism Disease
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Therapy Type:
  • Enzyme Replacement Therapy
  • Substrate Reduction Therapy
  • Small Molecule Drugs
  • Others
  • By Application:
  • Glycogen Metabolism Disease
  • Lipid Metabolism Disease
  • Amino Acid Metabolism Disease
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • Central Africa
  • South Africa
  • North Africa
  • Company Profiles
  • Merck & Co., Inc.*
  • Company Overview
  • Application Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
  • Novartis AG
  • Amicus Therapeutics
  • AstraZeneca Plc
  • Boehringer Ingelheim
  • Shire Plc
  • Sanofi Genzyme
  • BioMarin Pharmaceutical, Inc.
  • Horizon Pharma Plc
  • GlaxoSmithKline Plc
  • “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Therapy Type
    • Market Snippet, By Application
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • PEST Analysis
  • PORTER's Analysis
  • Regulatory Scenario

4. Global Metabolism Drugs Market, By Therapy Type, 2016 - 2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Enzyme Replacement Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
  • Substrate Reduction Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
  • Small Molecule Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)

5. Global Metabolism Drugs Market, By Application, 2016 - 2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Glycogen Metabolism Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
  • Lipid Metabolism Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
  • Amino Acid Metabolism Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)

6. Global Metabolism Drugs Market, By Distribution Channel, 2016 - 2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)

7. Global Metabolism Drugs Market, By Regions, 2016 - 2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2026
  • North America
    • Market Size and Forecast, By Therapy Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Therapy Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Therapy Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Market Size and Forecast, By Therapy Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Therapy Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • Central Africa
    • South Africa
    • North Africa
  • Middle East
    • Market Size and Forecast, By Therapy Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Company Profiles
    • Merck & Co., Inc.
    • Company Overview
    • Application Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Novartis AG
    • Company Overview
    • Application Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Amicus Therapeutics
    • Company Overview
    • Application Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • AstraZeneca Plc
    • Company Overview
    • Application Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Boehringer Ingelheim
    • Company Overview
    • Application Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Shire Plc
    • Company Overview
    • Application Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Sanofi Genzyme
    • Company Overview
    • Application Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • BioMarin Pharmaceutical, Inc.
    • Company Overview
    • Application Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Horizon Pharma Plc
    • Company Overview
    • Application Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • GlaxoSmithKline Plc
    • Company Overview
    • Application Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Section

  • References
  • Research Methodology
  • About Us and Sales Contact